MedTrace Logo

Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines

NCT00776438 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2015-06-17

No results posted yet for this study

Summary

To further characterize the immune responses induced after an influenza vaccination performed either via the ID or the IM routes in two clearly distinct populations.

Objectives:

* To describe the immune response per age group and vaccine group after vaccination.
* To describe the safety of the vaccines per age group and per vaccine group after vaccination.

Conditions

  • Influenza
  • Orthomyxovirus Infections
  • Myxovirus Infection

Interventions

BIOLOGICAL

Inactivated, split-virion, influenza vaccine

0.1 mL, Intradermal

BIOLOGICAL

Inactivated, split-virion, influenza vaccine

0.5 mL, Intramuscular

BIOLOGICAL

Inactivated, split-virion influenza vaccine

0.1 mL, Intradermal

BIOLOGICAL

Inactivated, split-virion influenza vaccine

0.5 mL, Intramuscular

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Sanofi Pasteur Inc

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-02-28
Completion
2009-04-30

Countries

  • France

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00776438 on ClinicalTrials.gov